These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11235597)

  • 21. Approaches to the management of postprandial hyperglycaemia.
    Landgraf R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S128-32. PubMed ID: 10522837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-prandial hyperglycaemia and vascular disease.
    Hanefeld M
    Int J Clin Pract Suppl; 2000 Sep; (112):13-8. PubMed ID: 11064946
    [No Abstract]   [Full Text] [Related]  

  • 24. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.
    Haffner SM
    Endocr Rev; 1998 Oct; 19(5):583-92. PubMed ID: 9793758
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus.
    Slama G
    Int J Clin Pract Suppl; 2000 Sep; (112):9-12. PubMed ID: 11064945
    [No Abstract]   [Full Text] [Related]  

  • 26. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
    Owens DR; Cozma LS; Luzio SD
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The burden of post-prandial hyperglycemia and its implications.
    Shah SN; Das AK
    J Assoc Physicians India; 2001 Jan; 49 Spec No():1-2. PubMed ID: 11245155
    [No Abstract]   [Full Text] [Related]  

  • 29. Importance of postprandial glucose control.
    Bell DS
    South Med J; 2001 Aug; 94(8):804-9. PubMed ID: 11549192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
    Winkler G; Baranyi E
    Orv Hetil; 2002 Oct; 143(43):2441-7. PubMed ID: 12455146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
    Gallagher A; Home PD
    Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.
    Meier JJ; Pennartz C; Schenker N; Menge BA; Schmidt WE; Heise T; Kapitza C; Veldhuis JD
    Diabetes Obes Metab; 2013 Mar; 15(3):258-63. PubMed ID: 23039360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
    Gin H; Rigalleau V
    Diabetes Metab; 2000 Sep; 26(4):265-72. PubMed ID: 11011218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.
    Gallwitz B
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S322-5. PubMed ID: 19875573
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes mellitus in the next decade: novel pipeline medications to treat hyperglycemia.
    Fonseca V
    Clin Ther; 2013 May; 35(5):714-23. PubMed ID: 23688536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
    Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes.
    Rave K; Heise T; Pfützner A; Boss AH
    Diabetes Care; 2007 Sep; 30(9):2307-8. PubMed ID: 17586744
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.